Harmony

BEHAVIORAL5 trials

Sponsors

University of North Carolina, Chapel Hill, MindRhythm, Inc., Massachusetts General Hospital, University of Witten/Herdecke, GlaxoSmithKline

Conditions

Goal AchievementHeart DiseasesHepatocellular CarcinomaHypertensionObesityOverweightPre-diabetesResilience, Psychological

Phase 4

A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with Type 2 diabetes mellitus (Harmony Outcomes Trial, GLP116174)

Active, not recruitingNL-OMON45225

GlaxoSmithKlinediabetes type 2

Start: 2015-07-01Target: 120Updated: 2024-02-28

Unknown Phase

The HARMONY Study: A Intervention to Reduce Cardiometabolic Risk in African American Women

CompletedNCT04705779

University of North Carolina, Chapel HillHeart Diseases, Hypertension, Obesity +4

Start: 2021-05-20End: 2025-02-07Updated: 2026-01-29

Detection of hEad Pulse for Ischemic StrOke Verification Study

MindRhythm, Inc.Stroke, Acute

Start: 2023-06-15End: 2023-10-01Target: 500Updated: 2023-07-28

Psychoeducational Intervention for Patients With Hepatocellular Carcinoma

RecruitingNCT06541990

Massachusetts General HospitalHepatocellular Carcinoma

Start: 2024-10-28End: 2026-09-30Target: 50Updated: 2025-08-29

App-based Stress Management With the mHealth Application "Harmony"

CompletedNCT06744452

University of Witten/HerdeckeGoal Achievement, Resilience, Psychological, Self Efficacy +2

Start: 2024-11-25End: 2025-03-03Updated: 2026-03-24

Related Papers

Protocol of the HARMONY study: A culturally relevant, randomized-controlled, stress management intervention to reduce cardiometabolic risk in African American women.

2024-06-10